Cerba supports oncologists, oncogeneticists, and all specialists in identifying genetic predispositions to cancer (constitutional oncogenetics) and in studying the genetic and molecular profile of tumors (somatic oncogenetics) to guide therapeutic management and prevention. To achieve this, our laboratory has the most innovative technologies and a dedicated team with a high level of expertise.
We carry out 10% of all tests for genetic predisposition to cancer in France, at the request of clinics, public hospitals and cancer centers. The tests, performed on Aviti high-throughput sequencers, benefit from optimal result delivery times, responding to the need for urgency in patient management (e.g. PARP inhibitor treatment). Several gene panels are proposed (breast/ovarian/prostate cancers, digestive cancers, Lynch syndrome, etc.). In all, the catalog includes over 80 predisposition genes, including all those currently recognized by learned societies such as the Groupe Génétique et Cancer (GGC) in France and the American Society of Clinical Oncology (ASCO).
Personalized medicine is developing at lightning speed in oncology, and we are supporting this dynamic by offering the most innovative tests to guide therapeutic management and the diagnosis of a large number of cancers (lung, colorectal, ovarian/breast, melanoma, pancreatic, neurological, urinary tract...).
- Rapid targeted tests, enabling certain alterations to be identified very quickly, giving access to targeted therapies in 1st line treatment (e.g. main mutations in the EGFR gene, in 4 to 5 calendar days).
- NGS analysis of DNA and RNA, enabling an exhaustive search, in 7 to 10 calendar days, for all alterations of interest (mutations, fusions, major rearrangements, HRD molecular signature, etc.).
Our panels are regularly reviewed to include the most innovative molecular targets, giving patients access to new molecules as part of clinical trials or early access.
Circulating tumour DNA ‘liquid biopsy’: a new approach to treatment
These analyses can be performed on fixed tumour tissue (FFPE), but also non-invasively on circulating tumour DNA. At the forefront of high-throughput sequencing since the early days of this technology, Cerba is reaffirming its pioneering status by being the first French laboratory to integrate the very latest generation of sequencers on its platform. This cutting-edge technology delivers unrivalled sequencing quality, maximising the chances of identifying alterations of therapeutic interest in circulating DNA.
Our expertise in oncology is based on a team of seven specialized biologists, in constant liaison with clinicians (regular participation “in RCP” multidisciplinary consultation meeting) and learned societies such as GFCO (French Oncology Cytogenomics Group). All are committed to providing comprehensive analysis reports. They are there to help you select the most appropriate tests and interpret the results.
